Articles

November 7, 2025

Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

September 3, 2025 PDF Version BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025, at 11:00 a.m. ET. The live webcast of the…

View details
CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) Study

CuraAX aims to address debilitating blood pressure drops and cognitive symptoms of nOH San Carlos, CA, – October 23, 2025 – CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced dosing of the first patient with CuraAX (CST-3056) in a Phase 2a proof-of-concept trial in…

View details